The molecular and cellular biology of pancreatic cancer

Critical Reviews in Eukaryotic Gene Expression

Volumn 8, Issue 3-4, 1998, Pages 377-393

  Perugini, Richard A ^a   McDade, Theodore P ^a   Vittimberga Jr , Frank J ^a   Callery, Mark P ^a  

^a University of Massachusetts   (United States)

Author keywords

Adenocarcinoma; Adhesion molecules; Growth factors; Oncogenes; Pancreas; Receptors; Signal transduction

Indexed keywords

ARTICLE; CANCER GROWTH; HUMAN; METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0032471806     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v8.i3-4.70     Document Type: Article

References (142)

1. Abruzzese JL, Gholson CF et al. (1992): A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 7:165-171.
2. Aizawa S, Sasaki M et al. (1996): p53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis. J Surg Oncol 62:279-283.
3. Akiyama T, Sudo C et al. (1986): The product of human cerbB-2 gene: a 185-kDa glycoprotein with tyrosine kinase activity. Science 232:1644-1646.
4. Almoguera C, Shibata D et al. (1988): Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554.
5. Altomonte M, Carbone A et al. (1992): Functional role of cell-adhesion molecules in the cell-mediated cytotoxicity of human melanoma cells.
6. Angel P, Karin M (1991): The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072:129-157.
7. Baldwin RL, Kobrin MS et al. (1996): Cytotoxic effects of TGF-alpha-Pseudomonas exotoxin A fusion protein in human pancreatic carcinoma cells. Pancreas 13(1):16-21.
8. Barton CM, Hall PA et al. (1991): Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163:111-116.
9. Bartsch D, Shevlin DW et al. (1996): Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst 88(10): 680-682.
10. Bevilacqua, M (1993): Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 11:767-804.
11. Bockman DE, Buchler M et al. (1994): Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 107:219-230.
12. Bos JL (1989): ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689.
13. Bos JL (1995): p21ras: an oncoprotein functioning in growth factor-induced signal transduction. Eur J Cancer 31A(7/ 8):1051-1054.
14. Bottinger EP, Jakubczak JL et al. (1997): Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J 16(10):2621-2633.
15. Brooks PC, Clark RAF et al. (1994): Requirement of vascular integrin αvβ3 for angiogenesis. Science 264: 569-571.
16. Chen Z, Zhang H et al. (1996): Gene deletion chemoselectivity: codeletion of the genes for p16 (INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 56(5):1083-1090.
17. Cheresh DA (1987): Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von-Willebrand factor. Proc Natl Acad Sci USA 84:6471-6475.
18. Clarke A, Purdie C et al. (1993): Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
19. Colletta G, Cirafici A et al. (1991): Constitutive expression of transforming growth factor α does not transform rat thyroid epithelial cells. Oncogene 6:583-587.
20. Cook T, Kvidera J et al. (1995): Cell-specific expression of dynamin in rat pancreas during acinar cell differentiation. Mol Cell Biol 6:405a.
21. Coussens L, Yang-Feng T et al. (1985): Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139.
22. Davies N, Kapur P et al. (1993): Transforming growth factor alpha is trophic to pancreatic cancer in vivo. Gut 34:1097-1098.
23. Day JD, Digiuseppe JA et al. (1996): Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27(2):119-124.
24. de Winter JP, Roelen BAJ et al. (1997): DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumor cells. Oncogene 14:1891-1899.
25. DelVillano B, Brennan S et al. (1983): Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA19-9. Clin Chem 29:549-552.
26. Detjen K, Fenrich MC et al. (1997): Tranfected cholecystokinin receptors mediated growth inhibitory effects on human pancreatic cancer cell lines. Gastroenterology 112:952-959.
27. Di Renzo MF, Poulsom R et al. (1995): Expression of the met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129-1138.
28. Dippold W, Lloyd K et al. (1980): Cell-surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc Natl Acad Sci USA 77:6114-6118.
29. Dorudi S, Sheffield J et al. (1993): E-cadherin expression in colorectal cancer - an immunocytochemical and in situ hybridization study. Am J Pathol 142:981-986.
30. Douglas BR, Woutersen RA et al. (1989): Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 96:462-469.
31. Dugan MC, Dergham ST et al. (1997): HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 14(3):229-236.
32. Ebert M, Yokoyama M et al. (1994): Coexpression of the cmet proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54:5775-5778.
33. El-Deiry WS, Tokino T et al. (1993): WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
34. Enari M, Hug H et al. (1995): Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81.
35. Filmus J, Shi W et al. (1993): Role of transforming growth fac-tor alpha (TGF-α) in the transformation of rastrans-fected rat intestinal epithelial cells. Oncogene 8:1017-1022.
36. Folkman J (1971): Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186.
37. Folsch UR, Winckler K et al. (1978): Influence of repeated administration of cholecystokinin and secretin on the pancreas of rat. Scand J Gastroenterol 13:663-671.
38. Fox S, Fawcett J et al. (1994): Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54:4539-4546.
39. Fox S, Turner G et al. (1995): The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol 177:369-376.
40. Friess H, Kobrin MS et al. (1992): Acidic and basic fibroblast growth factor and their receptors are expressed in the human pancreas. Pancreas 7:737.
41. Friess H, Yamanaka Y et al. (1993): Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856.
42. Funatomi H, Itakura J et al. (1997): Amphiregulin antisense oligonucleatide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 72:512-517.
43. Furukawa T, Duguid WP et al. (1995): Hepatocyte growth factor and met receptor expression in human pancreatic carcinogenesis. Am J Pathol 147(4):889-895.
44. Gansauge S, Gansauge F et al. (1997): Overexpression of cyclin D1 in human pancreatic cancer is associated with poor prognosis. Cancer Res 57:1634-1637.
45. Gjertsen MK, Saeterdal I et al. (1996): Characterization of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 74: 1828-1833.
46. Gospodarowicz D, Neufeld G et al. (1986): Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Differen 19:1-17.
47. waf1 expression and growth inhibition by transforming growth factor β involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57:3929-3934.
48. Grunewald K, Lyons J et al. (1989): High frequency of Kiras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041.
49. Gunthert U, Hofmann M et al. (1991): A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24.
50. Guo X, Friess H et al. (1996): KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 56(21):4876-4880.
51. Gupta M, Arciaga R et al. (1985): Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases: comparison with carcinoembryonic antigen. Cancer 56:277-283.
52. Hahn SA, Kern SE (1995): Molecular genetics of exocrine pancreatic neoplasms. Surg Clin NA 75(5):857-869.
53. Hahn SA, Schutte M et al. (1996): DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
54. Harper JW, Adami GR et al. (1993): The p21 cdk-interacting protein Cip21 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
55. Haynes B, Liao H et al. (1991): The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 3:347-350.
56. Hofmann M, Rudy W et al. (1993): A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 53:1516-1521.
57. Hofmann M, Rudy W et al. (1991): CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51:5292-5297.
58. Howatson AG, Carter DC (1985): Pancreatic carcinogenesis - enhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer 51:107-114.
59. Hu Z, Evarts RP et al. (1993): Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat. Am J Pathol 142(6):1823-1830.
60. Huang L, Goodrow T et al. (1996): Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 56(5): 1137-1141.
61. Hudd C, LaRegina MC et al. (1989): Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice. Am J Surg 157:386-394.
62. a in the adhesion of pancreatic carcinoma cells to activated endothelium. Int J Cancer 54:972-977.
63. Iwamura T, Caffrey TC et al. (1997): P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res 57:1206-1212.
64. Iyer A, Kmiecik TE et al. (1990): Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differen 1(2):87-95.
65. Jacob A, Kandpal G et al. (1996): Isolation of expressed sequences that include a gene for familial breast cancer (BRCA2) and other novel transcripts from a five megabase region on chromosome 13q12. Oncogene 13(1):213-221.
66. Jamal H, Cano-Gauci D et al. (1994): Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 9:417-423.
67. Johnson J, Stade B et al. (1989): De novo expression of intercellular adhesion molecule-1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86:641-644.
68. Kalthoff H, Schmiegel W et al. (1993): p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298.
69. Katagiri T, Nakamura Y et al. (1996): Mutations in the BRCA2 gene in hepatocellular carcinoma. Cancer Res 56:4575-4577.
70. Kawaguchi Y, Takebayashi H et al. (1997): Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Cancer Lett 116(1): 53-59.
71. Kawarada Y, Ishikura H et al. (1997): Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 15(3):251-257.
72. Kiehne K, Herzig K-H et al. (1997): c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas 15(1):35-40.
73. Klemke R, Yebra M et al. (1994): Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J Cell Biol 127:859-866.
74. Kloppel G, Bommer G et al. (1980): Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis. Virchows Archives Histol 387:221-233.
75. Korc M, Chandrasekar B et al. (1992): Overexpression of epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352-1360.
76. Kozuka S, Sassa R et al. (1979): Relation of pancreatic duct hyperplasia to carcinoma. Cancer 43:1418-1428.
77. Lane D (1992): p53: guardian of the genome. Nature 358: 15-16.
78. Leavesley D, Ferguson G et al. (1992): Requirement of the integrin β3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117:1101-1107.
79. Lei S, Appert HE et al. (1995): Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 17(1):15-21.
80. Lemoine NR, Hughes CM et al. (1992): The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7-12.
81. Los M, Craen M et al. (1995): Requirement of an ICE/CED-3 protease for Fas/APO-1 mediated apoptosis. Nature 375:81-83.
82. Lowe S, Schmitt E et al. (1993): p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849.
83. Lundin J, Nordling S et al. (1996): Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 53:104-111.
84. Mackay C, Terpe H-J et al. (1994): Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124:71-82.
85. Magnani J, Brockhaus M et al. (1981): A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 212:55-56.
86. Massague J, Pandiella A (1993): Membrane-anchored growth factors. Ann Rev Biochem 62:515-541.
87. Matrisian LM (1992): The matrix-degrading metalloproteinases. Bioessays 14:455.
88. Max R, Gerritson RRCM et al. (1997): Immunohistochemical analysis of integrin αvβ3 expression on tumorassociated vessels of human carcinomas. Int J Cancer 71:320-324.
89. Mayer B, Johnson J et al. (1993): E-cadherin expression in primary and metastatic gastric cancer: downregulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53:1690-1695.
90. McEver R, Beckstead J et al. (1989): GMP-40, a platelet α-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 84:92-99.
91. Meterissian SH (1997): Apoptosis: its role in the progression of and chemotherapy for carcinoma. J Am Coll Surg 184:658-666.
92. Militello C, Sperti C et al. (1997): Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Pancreas 14(3):222-228.
93. Most J, Schwaeble W et al. (1992): Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) on human monocytes and monocytic tumor cell lines. J Immunol 148:1635-1642.
94. Naik P, Karrim J et al. (1996): The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 10:2105-2116.
95. Nakamori S, Yashima K et al. (1995): Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 86:174-181.
96. Nakamura T, Nishizawa T et al. (1989): Molecular cloning and expression of the human hepatocyte growth factor. Nature 342(6248):440-443.
97. Nakata T, Iwamoto A et al. (1993): Predominant and developmentally regulated expression of dynamin in neurons. Neuron 7:461-469.
98. Naumann M, Savitskaia N et al. (1996): Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110 (4):1215-1224.
99. Pazin MJ, Williams LT (1992): Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci 17:374-378.
100. x. Science 250:1130-1132.
101. Pignatelli M, Ansari T et al. (1994): Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 174:243-248.
102. Povoski SP, Zhou W et al. (1994): Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors. Gastroenterology 107:1135-1146.
103. Rail C, Rustgi A (1995): CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 55:1831-1835.
104. Reber S, Matzku S et al. (1990): Retardation of metastatic growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 46:919-927.
105. Redston MS, Caldas C et al. (1994): p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033.
106. Rothlein R, Mainolfi E et al. (1991): A form of circulating ICAM-1 in human serum. J Immunol 147: 3788-3793.
107. Rudy W, Hofmann M et al. (1993): The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53:1262-1268.
108. Sakorafas GH, Lazaris A et al. (1995): Oncogenes in cancer of the pancreas. Eur J Surg Oncol 21:251-253.
109. Sakurai Y, Sawada T et al. (1997): Identification and characterization of motility stimulating factor secreted from pancreatic cancer cells: role in tumor invasion and metastasis. Clin Exp Metastasis 15(3):307-317.
110. Schafer H, Zheng J et al. (1996): PACAP stimulates transcription of c-Fos and c-Jun and activates the AP-1 transcription factor in rat pancreatic carcinoma cells. Biochem Biophys Res Commun 221:111-116.
111. Schafer H, Zheng J et al. (1996): Pituitary adenylate-cyclaseactivating polypeptide stimulates proto-oncogene expression and activates the AP-1 (c-Fos/c-Jun) transcription factor in AR4-2J pancreatic carcinoma cells. Eur J Biochem 242:467-476.
112. Schipper J, Frixen U et al. (1991): E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 51:6328-6337.
113. Schmielau J, Kalthoff H et al. (1996): The role of cytokines in pancreatic cancer. Int J Pancreatol 19(3):157-163.
114. Schwaeble W, Kerlin M et al. (1993): De novo expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in pancreas cancer. Int J Cancer 53:328-333.
115. Seiter B, Arch R et al. (1993): Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443-455.
116. Serrano M, Hannon GJ et al. (1993): A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
117. Shiozaki H, Tahara H et al. (1991): Expression of immunoreactive E-Cadherin adhesion molecules in human cancers. Am J Pathol 139:17-23.
118. Slamon D, Clark G et al. (1987): Human breast cancer: correlation of relapse and survival with amplification of the erbB-2/neu oncogene. Science 235:177-182.
119. Sonnenberg E, Meyer D et al. (1993): Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123(1):223-235.
120. Springer T, Dustin M et al. (1987): The lymphocyte-function associated LFA-1, CD-2, and LFA-3 molecules: cell-adhesion receptors of the immune system. Am Rev Immunol 5:223-252.
121. Stamenkvic I, Aruffo A et al. (1991): The hematopoetic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343-348.
122. Stoker M, Gherardi E et al. (1987): Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327(6119):239-242.
123. a. Biochem Biophys Res Commun 179:713-719.
124. Takebayashi H, Oida H et al. (1996): Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Cancer Res 56:4164-4170.
125. Tang C, Offerhous GJA et al. (1997): Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumor-free pancreas. Br J Cancer 75(10): 1467-1473.
126. Teng D, Bogden R et al. (1996): Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13(2):241-244.
127. Underhill C (1992): CD44: the hyaluronan receptor. J Cell Sci 103:293-298.
128. Valentich MA, Cook T et al. (1996): Expression of dynamin immunoreactivity in experimental pancreatic tumors induced in rat by mancozeb-nitrosomethylurea. Cancer Lett 102:23-29.
129. Wagner M, Cao T et al. (1996): Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer 68:782-787.
130. x determinant on myeloid and tumor cells. Science 250:1132-1135.
131. Watanabe M, Nobuta A et al. (1996): An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in Panc-1 pancreatic carcinoma cells. Int J Cancer 67:264-268.
132. Weidner N, Semple JP et al. (1991): Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8.
133. Weinberg DS, Ruggeri B et al. (1997): Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J Clin Invest 100(3):597-603.
134. Weinel RJ, Neumann K et al. (1996): Expression and potential role of E-cadherin in pancreatic carcinoma. Int J Pancreatol 19(1):25-30.
135. Whelan A, Bartsch D et al. (1995): Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333(15):975-977.
136. Xiong Y, Hannon GJ et al. (1993): p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
137. Yamanaka Y, Friess H et al. (1993): Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53(21):5289-5296.
138. Yamanaka Y, Friess H et al. (1993): Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-570.
139. Yamazaki K, Nagao T et al. (1997): Expression of basic fibroblast growth factor (FGF-2)-associated with tumor proliferation in human pancreatic carcinoma. Virchows Archives 431:95-101.
140. Yanagisawa A, Otake K et al. ( 1993): Frequent c-Ki-ras oncogene activation in mucous cell hyperplasia of pancreas suffering from chronic inflammation. Cancer Res 53:953-956.
141. Yebra M, Filardo EJ et al. (1995): Induction of carcinoma cell migration on vitronectin by NF-κB-dependent gene expression. Mol Biol Cell 6:841-850.
142. Zervos EE, Norman JG et al. (1997): Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367-371.